Read More

Conformis Shares Shoot Higher Following FDA Clearance For Actera Hip System

Conformis (NASDAQ: CFMS) has received 510(k) clearance from the U.S. Food and Drug Administration for its Actera Hip System. Actera utilizes an advanced tri-taper femur stem design that facilitates direct anterior approach total hip arthroplasties, and provides an additional stem option to orthopedic surgeons.

CFMS

Read More

Rhythm Secures European Commission Marketing Authorization For Genetic Disease Candidate

The European Commission (EC) has expanded the marketing authorization for Rhythm’s (NASDAQ: RYTM) lead drug product IMCIVREE (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age an

RYTM